12:00 AM
 | 
Feb 09, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Staccato alprazolam: Phase IIa started

Alexza began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 0.5, 1 and 2 mg inhaled Staccato in...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >